leisure time -WSS

leisure time

author：Wikipedia 2025-08-12 08:28:10 - browse：97

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Inside the rise of 'mukbang' eating videos

WSS

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Why Titanic fascinates society, still drawing tours to the wreckage

explore

leisure time

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Psychedelics group wrestles with new pharma identity

Xenotransplantation trials will require adjusting expectations, experts say

Tori Bowie and the unacceptable rates of Black maternal death

North Korean leader's powerful sister says warplanes repelled US spy plane

Alkermes shareholders re

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Hepatitis C has a cure — but many Americans still lack access to it

Inside the rise of 'mukbang' eating videos

focus

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Timeline: Key moments in fight for gay rights

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

FDA approves first new drug developed for postpartum depression

Sen. Bill Cassidy on how to lower drug prices

Xenotransplantation trials will require adjusting expectations, experts say

explore

focus

focus

leisure time